Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 9/20 | 0.49 |
| ▸ | PDE1A | P54750 | 8/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.49 |
| ▸ | PDE2A | O00408 | 5/20 | 0.49 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13334343 | 0.92 | PDE1B (0.42) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL2454858 | 0.87 | PDE1A (0.48) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL2454975 | 0.86 | PDE1B (0.51) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL9608337 | 0.85 | PDE1B (0.48) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL9608334 | 0.85 | PDE1B (0.52) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL2454720 | 0.84 | PDE1B (0.50) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL2537381 | 0.84 | PDE1B (0.45) | PDE1BPDE1APDE1CPDE2ADPP4 | |
| SCHEMBL3011746 | 0.84 | PDE1B (0.64) | PDE1BPDE1APDE1CPDE2ADPP4 | |
| SCHEMBL7505214 | 0.84 | PDE1A (0.48) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL7507537 | 0.83 | PDE1A (0.51) | PDE1BPDE1APDE1CPDE2ASLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11291666-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210213018-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10398698-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180177782-A9 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180177782-A9 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180000825-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-2367428-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20150353556-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-12-10 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2367428-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010065147-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065147-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000825-A1 | NOVEL USES | PDE2A, PDE5A, PDE3A | PDE1B 21/4885PDE1A 13/4885PDE1C 23/4885 |
| US-10398698-B2 | Uses | PDE5A, PDE2A, PDE3A | PDE1B 29/4885PDE1A 19/4885PDE1C 28/4885 |
| US-20150353556-A1 | ORGANIC COMPOUNDS | CYP2C9, TPMT, CYP2C19 | PDE1B 4863/4885PDE1A 4874/4885PDE1C 4862/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | PDE1B 17/4885PDE1A 10/4885PDE1C 15/4885 |
| US-20210213018-A1 | NOVEL USES | PDE2A, PDE4A, PDE1A | PDE1B 8/4885PDE1A 3/4885PDE1C 16/4885 |
| US-11291666-B2 | Uses | PDE2A, PDE3A, PDE5A | PDE1B 13/4885PDE1A 7/4885PDE1C 16/4885 |
| US-20120136013-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | PDE1B 4855/4885PDE1A 4874/4885PDE1C 4854/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE1B 22/4885PDE1A 13/4885PDE1C 14/4885 |
| US-20180177782-A9 | NOVEL USES | PDE2A, PDE5A, PDE3A | PDE1B 21/4885PDE1A 13/4885PDE1C 23/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | PDE1B 21/4885PDE1A 13/4885PDE1C 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.